SCHEMBL6449685

SCHEMBL6449685

CCOC(=O)c1cc(-c2ccc(OC)cc2)nn1-c1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.66
POLB P06746 2/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
APEX1 P27695 1/20 0.63
RECQL P46063 1/20 0.63
CTDSP1 Q9GZU7 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
MAPT P10636 2/20 0.61
HTT P42858 2/20 0.58
KMT2A Q03164 2/20 0.58
USP2 O75604 1/20 0.58
LMNA P02545 2/20 0.58
ALDH1A1 P00352 3/20 0.55
PTGS2 P35354 2/20 0.53
PTGS1 P23219 1/20 0.53
CHRNA7 P36544 1/20 0.53
PDE4D Q08499 1/20 0.52
ALOX5 P09917 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4012708 0.89 FAAH (0.60) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL5698596 0.89 ALDH1A1 (0.60) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL14132421 0.87 LMNA (0.70) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL6454672 0.82 ALDH1A1 (0.61) FAAHPOLBMAPTHTTLMNA
SCHEMBL1873573 0.81 PDE4D (0.61) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL9353410 0.80 CHRNA7 (0.72) FAAHPTGS2CHRNA7ALOX5CA9
SCHEMBL4692400 0.80 MAPT (0.66) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL8511661 0.80 KMT2A (0.60) FAAHPOLBMAPTKMT2ALMNA
SCHEMBL16112468 0.78 LMNA (0.73) FAAHPOLBL3MBTL1APEX1RECQL
SCHEMBL5022767 0.78 TSHR (0.58) FAAHPOLBTDP1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus ANADYS PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
WO-2004110351-A2 HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS ANADYS PHARMACEUTICALS, INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075375-A1 Heterocyclic compounds for treating hepatitis C virus HAVCR2, HCCS, LIPC FAAH 1707/4885POLB 2806/4885L3MBTL1 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.